May 27, 2021
Today, Oisín Biotechnologies, a well-known developer of senolytics, drugs that destroy harmful senescent cells, has announced that it has more than doubled its total funding through an oversubscribed round. This has taken its total funding from $4.5 million to $9.5 million. Why we Age: Cellular SenescenceAs your body ages, more of your cells become senescent....
May 25, 2018
BRINGING REJUVENATION BIOTECHNOLOGY AND INVESTORS TOGETHER At the Frederick P. Rose Auditorium, Cooper Union in New York City, we will be hosting a special one-day conference focused on aging research and biotech investment. Developing therapies from initial concepts, through clinical testing, and ultimately to market takes a pipeline, and right now, that pipeline is being...
